Skip to content

Mapping normal memory performance in different age groups: A Behavior-Genomics Study

Mapping normal memory performance in different age groups: A Behavior-Genomics Study - Cognition and genetics in different age groups

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON45595
Enrollment
290
Registered
2017-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geen aandoeningen nvt

Interventions

Age cohorts
Cognition
Genomics
Memory

Sponsors

Takeda
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. The subject has to sign and date a written informed consent form prior to the initiation of study procedures; 2. The subject falls in the age-range of one the cohorts, i.e. 18-30; 40-60; 60-80; 3. The subject has good comprehension of the Dutch language 4. Normal memory performance 5. The subject agrees with the fact that he or she will be informed about irregular findings with regard to their medical condition.

Exclusion criteria

Exclusion criteria: - Suffering from uncontrolled, clinically significant neurologic disease or other abnormality which may impact the ability of the subject to participate or potentially confound the study results, which includes pregnancy and having received chemo treatment during the past year. - The presence of psychiatric illness including schizophrenia, depression, bipolar disorder, Attention Deficit Hyperactivity Disorder and autism; - Smoking more than 10 cigarettes a day. - Excessive drinking, i.e. >20 glasses of alcohol containing beverages a week, - Current use of psychoactive medication (e.g. antidepressants, antipsychotics), centrally acting beta blockers, use of recreational drugs from 2 weeks before until the end of the yearly testing , - Any sensory or motor deficits which could reasonably be expected to affect test performance. - Consultation of a clinical expert for memory problems before having entered the study - Having received any investigational compound within 60 days prior to the Baseline (Screening) Visit

Design outcomes

Primary

MeasureTime frame
The primary outcome measure is genetic variation (DNA and RNA), which will be related to memory variation in the Verbal Learning Test (VLT).

Secondary

MeasureTime frame
In the eldest group, the Mini Mental State Examination will provide a more global indication on cognitive functioning. For all groups, functioning in related cognitive domains will be assessed using the Visual Association Test, Digit Span, Fluency, Letter Digit Substitution, Stroop, Trail Making Test, Paired Associate Learning, and Pattern Separation.

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)